Back to article

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (opens in new tab) 5 articles covering this post

investor.lilly.com··r/longevity·Open original

Cited by 5 articles

Next-gen weightloss drug retatrutide trial shows users lose almost a third of their body weight

scientificamerican.com

·

Retatrutide hits 28% weight loss in Phase 3

chamath.substack.com··Substack

Retatrutide's phase 3 results: 30% weight loss in 2 years

empirical.health··Hacker News

Retatrutide, ‘Triple G’ Anti-Obesity Drug, Leads to ‘Huge’ Weight Loss of Up to 85 Pounds

A newer, more powerful GLP-1 may do what only bariatric surgery could before

health.yahoo.com·